138 related articles for article (PubMed ID: 24996446)
1. Validation of the prognostic gene portfolio, ClinicoMolecular Triad Classification, using an independent prospective breast cancer cohort and external patient populations.
Wang DY; Done SJ; Mc Cready DR; Leong WL
Breast Cancer Res; 2014 Jul; 16(4):R71. PubMed ID: 24996446
[TBL] [Abstract][Full Text] [Related]
2. A new gene expression signature, the ClinicoMolecular Triad Classification, may improve prediction and prognostication of breast cancer at the time of diagnosis.
Wang DY; Done SJ; McCready DR; Boerner S; Kulkarni S; Leong WL
Breast Cancer Res; 2011 Sep; 13(5):R92. PubMed ID: 21939527
[TBL] [Abstract][Full Text] [Related]
3. Long non-coding RNA expression profiles predict metastasis in lymph node-negative breast cancer independently of traditional prognostic markers.
Sørensen KP; Thomassen M; Tan Q; Bak M; Cold S; Burton M; Larsen MJ; Kruse TA
Breast Cancer Res; 2015 Apr; 17(1):55. PubMed ID: 25887545
[TBL] [Abstract][Full Text] [Related]
4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer.
Acharya CR; Hsu DS; Anders CK; Anguiano A; Salter KH; Walters KS; Redman RC; Tuchman SA; Moylan CA; Mukherjee S; Barry WT; Dressman HK; Ginsburg GS; Marcom KP; Garman KS; Lyman GH; Nevins JR; Potti A
JAMA; 2008 Apr; 299(13):1574-87. PubMed ID: 18387932
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer.
Gong C; Tan W; Chen K; You N; Zhu S; Liang G; Xie X; Li Q; Zeng Y; Ouyang N; Li Z; Zeng M; Zhuang S; Lau WY; Liu Q; Yin D; Wang X; Su F; Song E
EBioMedicine; 2016 Sep; 11():199-209. PubMed ID: 27566954
[TBL] [Abstract][Full Text] [Related]
6. Identification and clinical validation of a multigene assay that interrogates the biology of cancer stem cells and predicts metastasis in breast cancer: A retrospective consecutive study.
Pece S; Disalvatore D; Tosoni D; Vecchi M; Confalonieri S; Bertalot G; Viale G; Colleoni M; Veronesi P; Galimberti V; Di Fiore PP
EBioMedicine; 2019 Apr; 42():352-362. PubMed ID: 30846393
[TBL] [Abstract][Full Text] [Related]
7. [Prognostic molecular classification of breast cancers based on gene expression profiling].
Feng YM; Li XQ; Sun BC; Gao XC; Gu L; Niu Y; Hao XS
Zhonghua Zhong Liu Za Zhi; 2006 Dec; 28(12):900-6. PubMed ID: 17533740
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
Ohnstad HO; Borgen E; Falk RS; Lien TG; Aaserud M; Sveli MAT; Kyte JA; Kristensen VN; Geitvik GA; Schlichting E; Wist EA; Sørlie T; Russnes HG; Naume B
Breast Cancer Res; 2017 Nov; 19(1):120. PubMed ID: 29137653
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort study.
Tang XR; Li YQ; Liang SB; Jiang W; Liu F; Ge WX; Tang LL; Mao YP; He QM; Yang XJ; Zhang Y; Wen X; Zhang J; Wang YQ; Zhang PP; Sun Y; Yun JP; Zeng J; Li L; Liu LZ; Liu N; Ma J
Lancet Oncol; 2018 Mar; 19(3):382-393. PubMed ID: 29428165
[TBL] [Abstract][Full Text] [Related]
10. An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk.
Yau C; Sninsky J; Kwok S; Wang A; Degnim A; Ingle JN; Gillett C; Tutt A; Waldman F; Moore D; Esserman L; Benz CC
Breast Cancer Res; 2013; 15(5):R103. PubMed ID: 24172169
[TBL] [Abstract][Full Text] [Related]
11. Unravelling site-specific breast cancer metastasis: a microRNA expression profiling study.
Schrijver WA; van Diest PJ; ; Moelans CB
Oncotarget; 2017 Jan; 8(2):3111-3123. PubMed ID: 27902972
[TBL] [Abstract][Full Text] [Related]
12. Molecular characteristics and metastasis predictor genes of triple-negative breast cancer: a clinical study of triple-negative breast carcinomas.
Kuo WH; Chang YY; Lai LC; Tsai MH; Hsiao CK; Chang KJ; Chuang EY
PLoS One; 2012; 7(9):e45831. PubMed ID: 23049873
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of microRNA-10b prognostic significance in a prospective cohort of breast cancer patients.
Parrella P; Barbano R; Pasculli B; Fontana A; Copetti M; Valori VM; Poeta ML; Perrone G; Righi D; Castelvetere M; Coco M; Balsamo T; Morritti M; Pellegrini F; Onetti-Muda A; Maiello E; Murgo R; Fazio VM
Mol Cancer; 2014 Jun; 13():142. PubMed ID: 24897960
[TBL] [Abstract][Full Text] [Related]
14. Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures.
Karn T; Pusztai L; Holtrich U; Iwamoto T; Shiang CY; Schmidt M; Müller V; Solbach C; Gaetje R; Hanker L; Ahr A; Liedtke C; Ruckhäberle E; Kaufmann M; Rody A
PLoS One; 2011; 6(12):e28403. PubMed ID: 22220191
[TBL] [Abstract][Full Text] [Related]
15. A gene-expression signature to predict survival in breast cancer across independent data sets.
Naderi A; Teschendorff AE; Barbosa-Morais NL; Pinder SE; Green AR; Powe DG; Robertson JF; Aparicio S; Ellis IO; Brenton JD; Caldas C
Oncogene; 2007 Mar; 26(10):1507-16. PubMed ID: 16936776
[TBL] [Abstract][Full Text] [Related]
16. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value.
Marisa L; de Reyniès A; Duval A; Selves J; Gaub MP; Vescovo L; Etienne-Grimaldi MC; Schiappa R; Guenot D; Ayadi M; Kirzin S; Chazal M; Fléjou JF; Benchimol D; Berger A; Lagarde A; Pencreach E; Piard F; Elias D; Parc Y; Olschwang S; Milano G; Laurent-Puig P; Boige V
PLoS Med; 2013; 10(5):e1001453. PubMed ID: 23700391
[TBL] [Abstract][Full Text] [Related]
17. Fuzzy logic selection as a new reliable tool to identify molecular grade signatures in breast cancer--the INNODIAG study.
Kempowsky-Hamon T; Valle C; Lacroix-Triki M; Hedjazi L; Trouilh L; Lamarre S; Labourdette D; Roger L; Mhamdi L; Dalenc F; Filleron T; Favre G; François JM; Le Lann MV; Anton-Leberre V
BMC Med Genomics; 2015 Feb; 8():3. PubMed ID: 25888889
[TBL] [Abstract][Full Text] [Related]
18. Molecular subtyping for clinically defined breast cancer subgroups.
Zhao X; Rødland EA; Tibshirani R; Plevritis S
Breast Cancer Res; 2015 Feb; 17(1):29. PubMed ID: 25849221
[TBL] [Abstract][Full Text] [Related]
19. A signature of epithelial-mesenchymal plasticity and stromal activation in primary tumor modulates late recurrence in breast cancer independent of disease subtype.
Cheng Q; Chang JT; Gwin WR; Zhu J; Ambs S; Geradts J; Lyerly HK
Breast Cancer Res; 2014 Jul; 16(4):407. PubMed ID: 25060555
[TBL] [Abstract][Full Text] [Related]
20. Large-scale tumor-associated collagen signatures identify high-risk breast cancer patients.
Xi G; Guo W; Kang D; Ma J; Fu F; Qiu L; Zheng L; He J; Fang N; Chen J; Li J; Zhuo S; Liao X; Tu H; Li L; Zhang Q; Wang C; Boppart SA; Chen J
Theranostics; 2021; 11(7):3229-3243. PubMed ID: 33537084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]